Non-Alcoholic Fatty Liver Disease in Long-Term Type 2 Diabetes: Role of rs738409 PNPLA3 and rs499765 FGF21 Polymorphisms and Serum Biomarkers

Autor(es):Mostrar menos -

Mana, Mauy Frujuello ; Parisi, Maria Candida R. ; Correa-Giannella, Maria Lucia ; Neto, Arnaldo Moura ; Yamanaka, Ademar ; Cunha-Silva, Marlone ; Cavaleiro, Ana Mercedes ; dos Santos, Cristina Rodrigues ; Pavan, Celia Regina ; Seva-Pereira, Tiago ; Dertkigil, Sergio S. J. ; Mazo, Daniel F.

• Tipo de documento: Artigo Científico
• Fonte: Molecules; v. 27, n. 10, p. 14-pg., 2022-05-01.

Resumo

Fibroblast growth factor 21 (FGF21) signaling and genetic factors are involved in non-alcoholic fatty liver disease (NAFLD) pathogenesis. However, these factors have rarely been studied in type 2 diabetes mellitus (T2D) patients from admixed populations such as in those of Brazil. Therefore, we aimed to evaluate rs738409 patanin-like phospholipase domain-containing protein (PNPLA3) and rs499765 FGF21 polymorphisms in T2D, and their association with NAFLD, liver fibrosis, and serum biomarkers (FGF21 and cytokeratin 18 levels). A total of 158 patients were included, and the frequency of NAFLD was 88.6%, which was independently associated with elevated body mass index. Significant liver fibrosis (>= F2) was detected by transient elastography (TE) in 26.8% of NAFLD patients, and was independently associated with obesity, low density lipoprotein, and gamma-glutamyl transferase (GGT). PNPLA3 GG genotype and GGT were independently associated with cirrhosis. PNPLA3 GG genotype patients had higher GGT and AST levels; PNPLA3 GG carriers had higher TE values than CG patients, and FGF21 CG genotype patients showed lower gamma-GT values than CC patients. No differences were found in serum values of FGF21 and CK18 in relation to the presence of NAFLD or liver fibrosis. The proportion of NAFLD patients with liver fibrosis was relevant in the present admixed T2D population, and was associated with PNPLA3 polymorphisms. (AU)

• Processo FAPESP: 18/17333-6 - Doença hepática gordurosa não alcoólica em diabéticos em seguimento em ambulatório de endocrinologia de hospital terciário
• Beneficiário: Daniel Ferraz de Campos Mazo
• Modalidade de apoio: Auxílio à Pesquisa - Regular